VivoSeq
Other

Helminthiasis

7

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

Helminthiasis is an early-stage landscape with 7 programs across 5 companies. The most active players are Zero Point Five Therapeutics, Bayer, Johnson & Johnson. 6 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Z

Zero Point Five Therapeutics

1 program

Phase 3Bayer logo

Bayer

2 programs

ApprovedJohnson & Johnson logo

Johnson & Johnson

1 program

ApprovedM

Medicines Development for Global Health

1 program

ApprovedC

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Completed1 · 50%

Clinical Trials

Trial Activity

Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676 for the Treatment of Soil Transmitted Helminthiasis (STH)
Recruiting·ZZero Point Five Therapeutics·Phase 3·NCT06128447·300 enrolled
Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 4·NCT02385058·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)